Stock Market Reviews

TERN (Terns Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on TERN (Terns Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Chugai buys a kidney biotech; ICER targets rising launch prices
  Chugai is acquiring partial rights to a marketed IgA nephropathy drug. Elsewhere, ICER claimed Americans are often “overpaying” for medicines and Summit raised $500 million.
  Oct 24, 2025 - $TERN
• Terns Pharmaceuticals Ends Obesity Program After TERN-601 Fails to Meet Phase 2 Trial Goals
  Terns Pharmaceuticals (TERN) said Wednesday it will not advance its investigational obesity drug TER
  Oct 22, 2025 - $TERN
• Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
  Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related Company will not advance TERN-601 or invest in other metabolic assets Reiterates focus on TERN-701, a potential best-in-class allosteric BCR-ABL inhibitor, for chronic myeloid leukemia with clinical data this quarter FO
  Oct 21, 2025 - $TERN
• We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Sep 30, 2025 - $TERN
• 2 Under-the-Radar Stocks That Could Soar
  They could ride the wave of the hottest therapeutic area in the industry.
  Sep 21, 2025 - $TERN
• Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
  Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ETFOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data release expected in fourth quarter of 2025. The
  Aug 21, 2025 - $TERN
• Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
  On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher. What Happened Lilly released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron that showed an average weight loss of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo, below the 15% expectations. Orforglipron
  Aug 7, 2025 - $TERN
• Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
  Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity completed enrollment; 12-week efficacy, safety and tolerability data expected in early 4Q25 Cash runway into 2028 focused on advancing CML program internally and partnering metabolic assets Terns to host a TERN-701-focused educational webinar in September 2025 FOSTER CITY, Calif., Aug. 05
  Aug 5, 2025 - $TERN
• Terns Pharmaceuticals CEO & Director Acquires 98% More Stock
  Even if it's not a huge purchase, we think it was good to see that Amy Burroughs, the CEO & Director of Terns...
  Jul 4, 2025 - $TERN
• Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
  Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o
  Jun 23, 2025 - $TERN